Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Alfentanil Hydrochloride Injection for Procedural Sedation and Analgesia

This study aims to find the suitable dose of remimazolam combined with alfentanil for sedation during gastroscopy in obese patients. We will use a biased coin up-and-down sequential design to identify the 90% effective dose (ED90).

Official registry: https://clinicaltrials.gov/study/NCT07925684 · Jianbo Wu · enrollment listed as 120

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Alfentanil Hydrochloride Injection, or Remimazolam Besylate for Injection. The registry lists allocation as randomized. This study aims to find the suitable dose of remimazolam combined with alfentanil for sedation during gastroscopy in obese patients.

They plan to enroll about 120 people at Jinan. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

ED₉₀ of Remimazolam Besylate Combined With Different Doses of Alfentanil for Inhibiting Gastroscopic Insertion Reactions in Obese Patients: A Dose-Finding Trial With Biased-Coin Sequential Allocation

Interventions: Alfentanil Hydrochloride Injection, Remimazolam Besylate for Injection

Primary outcome (registry wording): The primary outcome is the ED90 (90% effective dose) of remimazolam besylate combined with alfentanil for suppressing the gastroscopic insertion response in obese patients.

Who it is for (from inclusion criteria)

  • Ages 18 Years to 65 Years
  • Patients aged 18 to 65 years
  • Body mass index (body-mass index (BMI)) between 30 and 39.9 kg/m²
  • American Society of Anesthesiologists physical status grade I-II or stable grade III

Public study contact (from the registry)

Xiao Song

+86 15628773255

songxiao0364@163.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07925684 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07925684?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07925684?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary